Phase I Mp0112 wet AMD study: Results of a single escalating dose study with DARPin® MP0112 in wet AMD
S Wolf, EH Souied, M Mauget-Faysse… - … & Visual Science, 2011 - iovs.arvojournals.org
S Wolf, EH Souied, M Mauget-Faysse, F Devin, M Patel, UE Wolf-Schnurrbusch, M Stumpp…
Investigative Ophthalmology & Visual Science, 2011•iovs.arvojournals.orgPurpose:: To report the safety and preliminary efficacy of DARPin® MP0112 in patients with
wet AMD. DARPins® are a new class of small proteins with very attractive therapeutic
properties. The clinical study with DARPin® MP0112 assessed the safety and preliminary
efficacy measured by visual acuity (VA), fluorescein angiography (FA), and color fundus
photography during 16 weeks. Methods:: DARPin® MP0112 is an extremely potent VEGF
inhibitor with very long ocular half-life. Animal studies indicate that dosing frequency in …
wet AMD. DARPins® are a new class of small proteins with very attractive therapeutic
properties. The clinical study with DARPin® MP0112 assessed the safety and preliminary
efficacy measured by visual acuity (VA), fluorescein angiography (FA), and color fundus
photography during 16 weeks. Methods:: DARPin® MP0112 is an extremely potent VEGF
inhibitor with very long ocular half-life. Animal studies indicate that dosing frequency in …
Abstract
Purpose:: To report the safety and preliminary efficacy of DARPin® MP0112 in patients with wet AMD. DARPins® are a new class of small proteins with very attractive therapeutic properties. The clinical study with DARPin® MP0112 assessed the safety and preliminary efficacy measured by visual acuity (VA), fluorescein angiography (FA), and color fundus photography during 16 weeks.
Methods:: DARPin® MP0112 is an extremely potent VEGF inhibitor with very long ocular half-life. Animal studies indicate that dosing frequency in patients may be reduced 3-4fold compared to current standard therapy. The MP0112 wet AMD study is a Phase I/II, open-label, non-controlled, multicentre trial. The MP0112 wet AMD study consisted of 5 dose (0.04 mg; 0.15 mg; 0.4 mg; 1.0 mg; 2.0 mg MP0112) ascending cohorts. Eligible patients were aged> 50 years with diagnosed wet AMD who are treatment naïve and have a BCVA of 20/40 to 20/320 in the study eye at 4 meters. Four to nine patients were included per cohort and received a single dose of MP0112 as intravitreal injections.
Results:: Overall, MP0112 was safe and well tolerated. VA at baseline ranged from 32 to 72 ETDRS letters (median: 64 ETDRS letters). At the end of the 16 weeks follow-up all patient had stable or increased VA. At the 4 week visit, a total of 16 patients (50%) received rescue therapy. In the highest two dose groups, 8 of 10 patients had no disease progression for 8 weeks, and 7 of 10 patients for even 16 weeks. The most frequent adverse effect was a dose-related transient sterile inflammation that resolved without visual consequences.
Conclusions:: The results of this Phase I dose-escalation study demonstrate overall safety and efficacy of MP0112. The higher MP0112 doses show potential for quarterly dosing for the treatment of wet AMD. DARPin MP0112 represents a very promising new anti-VEGF treatment option with potential in various retinal diseases and is a showcase for a novel class of therapeutic proteins in ophthalmology.
Clinical Trial:: http://www. clinicaltrials. gov NCT01086761
ARVO Journals